Literature DB >> 34791154

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.

.   

Abstract

AIMS: Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19. METHODS AND
RESULTS: A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19.
CONCLUSION: This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities. This article has been co-published with permission in the European Heart Journal and Cardiovascular Research. © The European Society of Cardiology 2021. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.

Entities:  

Keywords:  ACE2; Acute coronary syndromes; Arrhythmias; Biomarkers; COVID-19; Cardiogenic shock; Heart failure; Myocarditis; Pulmonary embolism; Thrombosis; Venous thromboembolism

Mesh:

Year:  2022        PMID: 34791154      PMCID: PMC8690006          DOI: 10.1093/eurheartj/ehab697

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  37 in total

Review 1.  Cardiovascular complications of COVID-19 severe acute respiratory syndrome.

Authors:  Robert J Henning
Journal:  Am J Cardiovasc Dis       Date:  2022-08-15

2.  Inflammatory and Cardiac Biomarkers in Relation with Post-Acute COVID-19 and Mortality: What We Know after Successive Pandemic Waves.

Authors:  Catalina Lionte; Victorita Sorodoc; Raluca Ecaterina Haliga; Cristina Bologa; Alexandr Ceasovschih; Ovidiu Rusalim Petris; Adorata Elena Coman; Alexandra Stoica; Oana Sirbu; Gabriela Puha; Mihai Constantin; Gabriela Dumitrescu; Victoria Gorciac; Andrei-Costin Chelariu; Andreea Nicoleta Catana; Elisabeta Jaba; Laurentiu Sorodoc
Journal:  Diagnostics (Basel)       Date:  2022-06-02

3.  The impact of the COVID-19 pandemic on heart failure management: Global experience of the OPTIMIZE Heart Failure Care network.

Authors:  Martin R Cowie; Ricardo Mourilhe-Rocha; Hung-Yu Chang; Maurizio Volterrani; Ha Ngoc Ban; Denilson Campos de Albuquerque; Edward Chung; Cândida Fonseca; Yuri Lopatin; José Antonio Magaña Serrano; Lilyana Mircheva; Gustavo Adolfo Moncada-Paz; Zurab Pagava; Eugenio B Reyes; Clara Saldarriaga; Pedro Schwartzmann; David Sim Kheng Leng; Marcelo Trivi; Yoto Trifonov Yotov; Shelley Zieroth
Journal:  Int J Cardiol       Date:  2022-06-22       Impact factor: 4.039

4.  Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19.

Authors:  Carsten Schade Larsen
Journal:  Int J Infect Dis       Date:  2022-07-06       Impact factor: 12.074

Review 5.  Angiotensin Receptor Blockers in the Management of Hypertension: A Real-World Perspective and Current Recommendations.

Authors:  Giovanna Gallo; Massimo Volpe; Speranza Rubattu
Journal:  Vasc Health Risk Manag       Date:  2022-07-11

6.  Acute Coronary Syndromes and SARS-CoV-2 Infection: Results From an Observational Multicenter Registry During the Second Pandemic Spread in Lombardy.

Authors:  Marco Ferlini; Diego Castini; Giulia Ferrante; Giancarlo Marenzi; Matteo Montorfano; Stefano Savonitto; Maurizio D'Urbano; Corrado Lettieri; Claudio Cuccia; Marcello Marino; Luigi Oltrona Visconti; Stefano Carugo
Journal:  Front Cardiovasc Med       Date:  2022-06-16

7.  Epidemiology of COVID-19 and Its Cardiac and Neurologic Complications Among Chinese and South Asians in Ontario: Waves 1, 2, and 3.

Authors:  Joseph Y Chu; Gordon W Moe; Manav V Vyas; Robert Chen; Chi-Ming Chow; Milan Gupta; Yosuf Kaliwal; Maria Koh; Dennis T Ko; Peter P Liu
Journal:  CJC Open       Date:  2022-06-27

8.  ST-Elevation Myocardial Infarction With Occluded Culprit Coronary Artery in a Young Patient Recovered From Mild COVID-19: A Case Report.

Authors:  Juan Manuel Muñoz Moreno; Anthony Ramos-Yataco; Erik Villanueva Garcia; Carlos Holguin Palacios; Gina Sánchez Sánchez
Journal:  Cureus       Date:  2022-09-17

Review 9.  Acute Myocardial Infarction During the COVID-19 Pandemic: An Update on Clinical Characteristics and Outcomes.

Authors:  Olga Toscano; Nicola Cosentino; Jeness Campodonico; Antonio L Bartorelli; Giancarlo Marenzi
Journal:  Front Cardiovasc Med       Date:  2021-12-23

10.  Evolution of Echocardiographic Abnormalities Identified in Previously Healthy Individuals Recovering from COVID-19.

Authors:  Cristina Tudoran; Mariana Tudoran; Talida Georgiana Cut; Voichita Elena Lazureanu; Cristian Oancea; Adelina Raluca Marinescu; Silvius Alexandru Pescariu; Gheorghe Nicusor Pop; Felix Bende
Journal:  J Pers Med       Date:  2022-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.